Capelville Dialysis Center is a medicare approved dialysis facility center in Memphis, Tennessee and it has 24 dialysis stations. It is located in Shelby county at 7008 E Shelby Dr, Memphis, TN, 38125. You can reach out to the office of Capelville Dialysis Center at (901) 757-5001. This dialysis clinic is managed and/or owned by Davita. Capelville Dialysis Center has the following ownership type - Profit. It was first certified by medicare in December, 2009. The medicare id for this facility is 442692 and it accepts patients under medicare ESRD program.
| Name | Capelville Dialysis Center |
|---|---|
| Location | 7008 E Shelby Dr, Memphis, Tennessee |
| No. of Dialysis Stations | 24 |
| Medicare ID | 442692 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 7008 E Shelby Dr, Memphis, Tennessee, 38125 | |
| (901) 757-5001 | |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
| NPI Number | 1255578837 |
| Organization Name | Capelville Dialysis Center |
| Doing Business As | Capelville Dialysis Llc |
| Address | 7008 E Shelby Dr Memphis, Tennessee, 38125 |
| Phone Number | (901) 757-5001 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 61% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 17% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 22% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 43% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 46% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 14% |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 46% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 26% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 28% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 39% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 44% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 12% |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 79% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 21% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 49% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 33% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 12% |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 26 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 12 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 67 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 539 |
| Percentage of adult patients getting regular hemodialysis at the center | 94 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Capelville Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 68 |
| Hypercalcemia patient months | 542 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 71 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 41 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 15 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 68 |
| Patient months included in arterial venous fistula and catheter summaries | 387 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 76 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 11 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 55 |
| Hospitalization Rate in facility | 181.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 321.9 |
| Hospitalization Rate: Lower Confidence Limit | 106.7 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at Capelville Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 42.6 (Worse than Expected) |
| Readmission Rate: Upper Confidence Limit | 56.4 |
| Readmission Rate: Lower Confidence Limit | 29.7 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Capelville Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .23 (As Expected) |
| SIR: Upper Confidence Limit | 1.13 |
| SIR: Lower Confidence Limit | .01 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Capelville Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 47 |
| Transfusion Rate in facility | 48.3 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 128.6 |
| Transfusion Rate: Lower Confidence Limit | 20.4 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at Capelville Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 265 |
| Mortality Rate in facility | 24.9 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 34.1 |
| Mortality Rate: Lower Confidence Limit | 17.7 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago
Memphis Central Dialysis Location: 889 Dr. M. L. King Jr. Ave, Memphis, Tennessee, 38126 Phone: (901) 525-1719 |
Memphis East Dialysis Location: 50 Humphreys Blvd Ste 42, Memphis, Tennessee, 38120 Phone: (901) 747-2316 |
News Archive
Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.
The level of inequalities in premature mortality between different areas of Britain has almost surpassed those seen shortly before the economic crash of 1929 and the economic depression of the 1930s, according to a new study published on bmj.com today.
Patient satisfaction has an increasing impact on hospitals' bottom lines, factoring into Medicare reimbursement of hospital care. A new study finds patients placed in Contact Precautions (Contact Isolation) were twice as likely to report perceived problems with care compared to patients without Contact Precautions, placing the common infection control practice at odds with hospital interests.
In a small village in West Bengal, India, 7-month-old Anwesha is oblivious to the fact that in her community, for generations before her, many newborns did not even live to see their first birthday. In an age old tradition, the community believed that the survival of the newborn or the mother is pre-determined and no extra care or immunization should interfere with the inevitable. It was only after persistent effort by CRY-supported project SSDC for a decade that the attitude of the community began to change.
Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 1 days ago